Further, Ad5-yCD/mutTKSR39rep-hIL12 treatment improved induction of antitumor immune response through expression of hIL12, as evidenced by activation of NKs and secretion of IFN-γ by cytotoxic T lymphocytes (CTL) against tumor cells (51). The gene discussed is IFNG; the disease is neoplasm.